Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | DGKA | P23743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3441345 | 0.95 | — | — | |
| SCHEMBL13778515 | 0.95 | — | — | |
| SCHEMBL1263525 | 0.95 | — | — | |
| SCHEMBL11769969 | 0.88 | THRB (0.42) | THRBHIF1AALDH1A1LMNATSHR | |
| SCHEMBL12459957 | 0.88 | THRB (0.42) | THRBHIF1AALDH1A1LMNATSHR | |
| SCHEMBL11257369 | 0.86 | USP2 (0.41) | THRBHIF1AALDH1A1LMNATSHR | |
| SCHEMBL15503338 | 0.86 | USP2 (0.41) | THRBHIF1AALDH1A1LMNATSHR | |
| SCHEMBL8523649 | 0.86 | USP2 (0.41) | THRBHIF1AALDH1A1LMNATSHR | |
| SCHEMBL17984926 | 0.84 | THRB (0.42) | THRBHIF1ATSHR | |
| SCHEMBL28218542 | 0.84 | HIF1A (0.41) | THRBHIF1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173947-B2 | Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
| US-8815227-B2 | Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom | NEKTAR THERAPEUTICS (US) | 2014-08-26 | — | — | US | disclosed |
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20130331549-A1 | Hydroxyapatite-Targeting Multiarm Polymers and Conjugates Made Therefrom | NEKTAR THERAPEUTICS (US) | 2013-12-12 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-7511094-B2 | 2-methylbutyraldehyde diethyl acetal end capped polyoxyethylene glycol; polyalkylene oxide, polyivnylpyrrolidone, polyvinyl alcohol, polyoxazoline etc. endcapped with polyetherpolyamine copolymers or oligomers covalently attached to diacetal tetramethylene group | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20060194940-A1 | 2-methylbutyraldehyde diethyl acetal end capped polyoxyethylene glycol; polyalkylene oxide, polyivnylpyrrolidone, polyvinyl alcohol, polyoxazoline etc. endcapped with polyetherpolyamine copolymers or oligomers covalently attached to diacetal tetramethylene group | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | THRB 4235/4885HIF1A 1622/4885ALDH1A1 1054/4885 |
| US-20130331549-A1 | Hydroxyapatite-Targeting Multiarm Polymers and Conjugates Made Therefrom | CD44, FGF23, PTH1R | THRB 2931/4885HIF1A 802/4885ALDH1A1 2579/4885 |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | THRB 4235/4885HIF1A 1622/4885ALDH1A1 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.